Literature DB >> 3918102

Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.

A H Rook, J J Hooks, G V Quinnan, H C Lane, J F Manischewitz, A M Macher, H Masur, A S Fauci, J Y Djeu.   

Abstract

Patients with the acquired immunodeficiency syndrome (AIDS) exhibit a variety of disorders of cellular immunity, including a deficient ability to generate cytotoxic T cells and depressed levels of natural killer (NK) cell activity. Interleukin 2 (IL 2) in vitro can markedly augment these depressed immune functions. Because IL 2 can induce the release of interferon-gamma (IFN-gamma) from normal peripheral blood lymphocytes (PBL), and because IFN-gamma may play a role in the regulation of NK cell activity, this study was performed to determine if the IL 2 enhancement of the NK cell activity of patients with AIDS was an IFN-gamma-dependent effect. PBL from eight healthy heterosexual donors and from nine patients with AIDS were studied for their ability to release IFN-gamma in response to IL 2 at a concentration of 100 U/ml. After 60 hr of culture, the PBL of all eight healthy donors produced IFN-gamma with a mean titer of 113 U/ml (range 40 to 320 U/ml). In contrast, the PBL from only two of nine patients with AIDS released measurable amounts of IFN-gamma (40 U/ml each) in response to IL 2 with a mean titer of 13.5 U/ml for all nine. Although the PBL from patients with AIDS were deficient in their capacity to produce IFN-gamma in response to 100 U/ml of IL 2, significant enhancement of NK cell activity could be obtained after only 1 hr of PBL treatment with 10 U/ml of IL 2, with an optimal NK enhancing effect occurring at doses of 50 to 100 U/ml of IL 2. The use of an anti-IFN-gamma monoclonal antibody resulted in complete neutralization of the IFN released from the normal PBL cultured with IL 2, but failed to inhibit the IL 2 enhancement of NK cell activity. Exogenous IFN-gamma exhibited different kinetics of enhancement of NK cell activity when compared to IL 2, requiring substantially more than 1 hr of pretreatment of PBL. These results indicate that the PBL from patients with AIDS usually do not release IFN-gamma when cultured with IL 2, and that IL 2 enhancement of the depressed NK cell activity of these patients may be an IFN-gamma-independent event. These results may have important implications for the therapy of AIDS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets.

Authors:  M Ito; S Bandyopadhyay; M Matsumoto-Kobayashi; S C Clark; D Miller; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts.

Authors:  S Bandyopadhyay; D S Miller; M Matsumoto-Kobayashi; S C Clark; S E Starr
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

Review 3.  A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection.

Authors:  S C Piscitelli; N Bhat; A Pau
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

4.  Treatment of the acquired immune deficiency syndrome.

Authors:  S Gupta; M S Gottlieb
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

Review 5.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

6.  Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.

Authors:  T Itoh; Y Sakata; Y Yoshida; K Tsushima; H Suzuki; S Saitoh; Y Tamura; H Ogasawara; N Sugimoto; H Takemori
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus.

Authors:  M Zaitseva; H Golding; J Manischewitz; D Webb; B Golding
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

8.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

9.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  B Y Lieberman; C Fiocchi; K R Youngman; W K Sapatnekar; M R Proffitt
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

10.  Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Tabuse; K Kuribayashi; K Saito
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.